[iooi]

> After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.2% in the pembrolizumab-combination group versus 49.4% in the placebo-combination group.

Seriously groundbreaking. This is a once-in-a-decade paper. [1]

[1] http://www.nejm.org/doi/full/10.1056/NEJMoa1801005?query=fea...

[mft_]

There have been lots of similar 'groundbreaking' data from the various anti-PD1/-PDL1s over the pest few years. This is great, but not greater than lots of others.